CY1121081T1 - Samidorphan (alks 33) σε συνδυασμο με βουπρενορφινη για την θεραπεια καταθλιπτικων διαταραχων - Google Patents

Samidorphan (alks 33) σε συνδυασμο με βουπρενορφινη για την θεραπεια καταθλιπτικων διαταραχων

Info

Publication number
CY1121081T1
CY1121081T1 CY181101356T CY181101356T CY1121081T1 CY 1121081 T1 CY1121081 T1 CY 1121081T1 CY 181101356 T CY181101356 T CY 181101356T CY 181101356 T CY181101356 T CY 181101356T CY 1121081 T1 CY1121081 T1 CY 1121081T1
Authority
CY
Cyprus
Prior art keywords
samidorphan
buprenorphin
alks
treatment
combination
Prior art date
Application number
CY181101356T
Other languages
English (en)
Inventor
Daniel Deaver
Elliot Ehrich
Original Assignee
Alkermes Pharma Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkermes Pharma Ireland Ltd filed Critical Alkermes Pharma Ireland Ltd
Publication of CY1121081T1 publication Critical patent/CY1121081T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η εφεύρεση αφορά μια σύνθεση που περιλαμβάνει βουπρενοφρίνη και έναν ανταγωνιστή υποδοχέα οπιούχων μ, όπου η σύνθεση χαρακτηρίζεται από έναν δείκτη δραστηριότητας ανταγωνιστών:αγωνιστών (AAnAI) μεταξύ περίπου 0.7 και περίπου 2.2 όπου = AAnAI/EC50 c max BUP c max ανταγωνιστή / IC 50.
CY181101356T 2011-12-15 2018-12-18 Samidorphan (alks 33) σε συνδυασμο με βουπρενορφινη για την θεραπεια καταθλιπτικων διαταραχων CY1121081T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161576233P 2011-12-15 2011-12-15
PCT/IB2012/002900 WO2013088243A1 (en) 2011-12-15 2012-12-14 Compositions of buprenorphine and mu-opioid receptor antagonists
EP12830900.2A EP2790702B1 (en) 2011-12-15 2012-12-14 Compositions of buprenorphine and mu-opioid receptor antagonists

Publications (1)

Publication Number Publication Date
CY1121081T1 true CY1121081T1 (el) 2019-12-11

Family

ID=47757653

Family Applications (1)

Application Number Title Priority Date Filing Date
CY181101356T CY1121081T1 (el) 2011-12-15 2018-12-18 Samidorphan (alks 33) σε συνδυασμο με βουπρενορφινη για την θεραπεια καταθλιπτικων διαταραχων

Country Status (24)

Country Link
US (8) US8822488B2 (el)
EP (3) EP3415148A1 (el)
JP (2) JP6038170B2 (el)
KR (1) KR101996108B1 (el)
CN (2) CN106727562B (el)
AU (1) AU2012351806C1 (el)
BR (1) BR112014012409B8 (el)
CA (1) CA2858812C (el)
CY (1) CY1121081T1 (el)
DK (1) DK3153171T3 (el)
EA (1) EA030609B8 (el)
ES (2) ES2692771T3 (el)
HR (1) HRP20181950T1 (el)
HU (1) HUE041883T2 (el)
IL (1) IL232785B (el)
LT (1) LT3153171T (el)
MX (1) MX2014007042A (el)
PL (1) PL3153171T3 (el)
PT (1) PT3153171T (el)
RS (1) RS58322B1 (el)
SI (1) SI3153171T1 (el)
TR (1) TR201815154T4 (el)
WO (1) WO2013088243A1 (el)
ZA (1) ZA201405029B (el)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2506712T3 (da) 2009-12-04 2019-06-03 Alkermes Pharma Ireland Ltd Morfinanderivater til behandling af lægemiddeloverdosering
HUE041981T2 (hu) 2010-08-23 2019-06-28 Alkermes Pharma Ireland Ltd Eljárások antipszichotikum által kiváltott súlygyarapodás kezelésére
US9211293B2 (en) 2011-12-15 2015-12-15 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
EP3415148A1 (en) * 2011-12-15 2018-12-19 Alkermes Pharma Ireland Limited Compositions of buprenorphine and mu-opioid receptor antagonists
ES2770978T3 (es) 2013-05-24 2020-07-06 Alkermes Pharma Ireland Ltd Análogos de morfanos y morfinanos y métodos de uso
WO2014190271A2 (en) 2013-05-24 2014-11-27 Alkermes Pharma Ireland Limted Methods for treating depressive symptoms
AR103598A1 (es) 2015-02-02 2017-05-24 Forma Therapeutics Inc Ácidos bicíclicos[4,6,0]hidroxámicos como inhibidores de hdac
JP6668362B2 (ja) 2015-02-02 2020-03-18 フォーマ セラピューティクス，インコーポレイテッド Ｈｄａｃ阻害薬としての３−アルキル−４−アミド−二環式［４，５，０］ヒドロキサム酸
US10555935B2 (en) 2016-06-17 2020-02-11 Forma Therapeutics, Inc. 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors
EP4243768A1 (en) 2020-11-12 2023-09-20 Alkermes Pharma Ireland Limited Immediate release multilayer tablet

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH581624A5 (el) 1970-08-14 1976-11-15 Sumitomo Chemical Co
US3856795A (en) 1972-04-25 1974-12-24 American Home Prod Process for preparation of secondary amines from tertiary amines
US3957793A (en) 1974-09-20 1976-05-18 Sterling Drug Inc. Hydroxyiminobenzazocines
US4032529A (en) 1974-09-20 1977-06-28 Sterling Drug Inc. Aminomethanobenzazocine intermediates
US4127577A (en) 1975-11-24 1978-11-28 Sterling Drug Inc. Aminomethanobenzazocine process
US4205171A (en) 1976-01-12 1980-05-27 Sterling Drug Inc. Aminomethanobenzazocines and nitromethanobenzazocines
US4464378A (en) 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
GB8332556D0 (en) * 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
US4649200A (en) 1986-05-08 1987-03-10 Regents Of The University Of Minnesota Substituted pyrroles with opioid receptor activity
US4939264A (en) 1986-07-14 1990-07-03 Abbott Laboratories Immunoassay for opiate alkaloids and their metabolites; tracers, immunogens and antibodies
US5258386A (en) 1991-06-05 1993-11-02 The United States Of America As Represented By The Secretary Of The Army (+)-3-substituted-N alkylmorphinans, synthesis and use as anticonvulsant and neuroprotective agents
US5607941A (en) 1992-06-26 1997-03-04 Boehringer Ingelheim Kg Useful for treating neurodegenerative diseases
SE9103745D0 (sv) 1991-12-18 1991-12-18 Wikstroem Haakan Aryl-triflates and related compounds
EP0632041A1 (en) 1993-07-01 1995-01-04 Katholieke Universiteit Nijmegen New morphine derivatives having improved analgesic and narcotic properties
WO1997025331A1 (en) 1996-01-10 1997-07-17 Smithkline Beecham S.P.A. Heterocycle-condensed morphinoid derivatives (ii)
GB9709972D0 (en) 1997-05-19 1997-07-09 Pfizer Ltd Tetrazoles
US7534866B2 (en) * 2005-10-19 2009-05-19 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
GB9912411D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
ES2304477T3 (es) 2000-10-31 2008-10-16 Rensselaer Polytechnic Institute Procedimiento de preparacion de compuestos con afinidad a receptores opioides.
WO2003079945A1 (en) * 2002-03-20 2003-10-02 Euro-Celtique S.A. Method of administering buprenorphine to treat depression
WO2003101963A1 (en) 2002-05-30 2003-12-11 Eli Lilly And Company Opioid receptor antagonists
MXPA06013270A (es) 2004-05-14 2007-04-23 Johnson & Johnson Compuestos de opioide carboxamido.
US20060063792A1 (en) 2004-09-17 2006-03-23 Adolor Corporation Substituted morphinans and methods of their use
JP5198067B2 (ja) 2004-11-05 2013-05-15 レンセラール ポリテクニック インスティチュート ４−ヒドロキシベンゾモルファン
ATE450524T1 (de) 2005-03-02 2009-12-15 Nycomed Gmbh (2r,4ar,10br)-6-(2,6-dimethoxypyridin-3-yl)-9- ethoxy-8-methoxy-1,2,3,4,4a,10b- hexahydrophenanthridin-2-ol hydrochloridsalz
ES2423485T3 (es) 2007-03-19 2013-09-20 Acadia Pharmaceuticals Inc. Asociaciones de agonistas y antagonistas inversos 5-HT2A con antipsicóticos
KR101519682B1 (ko) 2007-08-09 2015-05-19 렌슬러 폴리테크닉 인스티튜트 4급 오피오이드 카르복스아미드
EP2252150B1 (en) * 2008-02-14 2018-04-11 Alkermes, Inc. Selective opioid compounds
US8138169B2 (en) * 2008-04-11 2012-03-20 Comgenrx, Inc. Combination therapy for bipolar disorder
JP5555890B2 (ja) * 2009-03-19 2014-07-23 アルカーメス ファーマ アイルランド リミテッド 高い経口バイオアベイラビリティを有するモルフィナン誘導体
US20120149724A1 (en) 2009-06-04 2012-06-14 The General Hospital Corporation Modulating endogenous beta-endorphin levels
US8530479B2 (en) * 2009-08-10 2013-09-10 Daljit Singh Dhanoa Deuterium-enriched alkyl sulfonamides
DK2506712T3 (da) * 2009-12-04 2019-06-03 Alkermes Pharma Ireland Ltd Morfinanderivater til behandling af lægemiddeloverdosering
EP3415148A1 (en) * 2011-12-15 2018-12-19 Alkermes Pharma Ireland Limited Compositions of buprenorphine and mu-opioid receptor antagonists
US9211293B2 (en) * 2011-12-15 2015-12-15 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
WO2014190271A2 (en) * 2013-05-24 2014-11-27 Alkermes Pharma Ireland Limted Methods for treating depressive symptoms

Also Published As

Publication number Publication date
KR101996108B1 (ko) 2019-10-01
US20130190342A1 (en) 2013-07-25
EP2790702A1 (en) 2014-10-22
TR201815154T4 (tr) 2018-11-21
CN106727562B (zh) 2019-07-05
ES2692771T3 (es) 2018-12-05
SI3153171T1 (sl) 2019-01-31
HUE041883T2 (hu) 2019-06-28
US20160256450A1 (en) 2016-09-08
ES2791764T3 (es) 2020-11-05
BR112014012409B8 (pt) 2022-09-13
US20150051240A1 (en) 2015-02-19
US8822488B2 (en) 2014-09-02
JP6403726B2 (ja) 2018-10-10
BR112014012409A2 (pt) 2017-06-13
IL232785A0 (en) 2014-07-31
RS58322B1 (sr) 2019-03-29
DK3153171T3 (en) 2018-11-19
WO2013088243A1 (en) 2013-06-20
CN106727562A (zh) 2017-05-31
US20180078542A1 (en) 2018-03-22
ZA201405029B (en) 2015-10-28
EP3415148A1 (en) 2018-12-19
EP2790702B1 (en) 2020-04-01
KR20140107258A (ko) 2014-09-04
US20210196703A1 (en) 2021-07-01
AU2012351806B2 (en) 2016-03-10
JP2015505853A (ja) 2015-02-26
LT3153171T (lt) 2018-12-10
EA030609B1 (ru) 2018-08-31
US10806731B2 (en) 2020-10-20
CN104159586A (zh) 2014-11-19
US20170056392A1 (en) 2017-03-02
JP6038170B2 (ja) 2016-12-07
US9913837B2 (en) 2018-03-13
EA201491153A1 (ru) 2015-04-30
US10314838B2 (en) 2019-06-11
BR112014012409B1 (pt) 2022-08-23
US9498474B2 (en) 2016-11-22
PL3153171T3 (pl) 2019-02-28
US20190247387A1 (en) 2019-08-15
US10188643B2 (en) 2019-01-29
IL232785B (en) 2021-04-29
AU2012351806A1 (en) 2014-05-15
US20180078543A1 (en) 2018-03-22
EA030609B8 (ru) 2018-10-31
HRP20181950T1 (hr) 2019-03-22
CA2858812A1 (en) 2013-06-20
JP2016222706A (ja) 2016-12-28
AU2012351806C1 (en) 2016-06-16
CA2858812C (en) 2019-02-26
EP3153171A1 (en) 2017-04-12
EP3153171B1 (en) 2018-09-19
NZ624056A (en) 2016-07-29
MX2014007042A (es) 2015-01-22
US9918978B2 (en) 2018-03-20
PT3153171T (pt) 2018-11-16

Similar Documents

Publication Publication Date Title
CY1121081T1 (el) Samidorphan (alks 33) σε συνδυασμο με βουπρενορφινη για την θεραπεια καταθλιπτικων διαταραχων
CY1123365T1 (el) Ενωσεις που εχουν δραστικοτητα ανταγωνιστη μουσκαρινικου υποδοχεα και αγωνιστη βητα2 αδρενεργικου υποδοχεα
CY1123590T1 (el) Θεραπειες που βασιζονται σε προσδετη χημειοαισθητηριου υποδοχεα
EA201300869A1 (ru) Морфинановые соединения
CY1117696T1 (el) ΝΕΑ ΠΑΡΑΓΩΓΑ ΚΥΚΛΟΕΞΥΛΑΜΙΝΗΣ ΜΕ ΔΡΑΣΕΙΣ β2 ΑΔΡΕΝΕΡΓΙΚΟΥ ΑΓΩΝΙΣΤΗ ΚΑΙ Μ3 ΜΟΥΣΚΑΡΙΝΙΚΟΥ ΑΝΤΑΓΩΝΙΣΤΗ
MY169479A (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
CY1118352T1 (el) Νεα παραγωγα κυκλοεξυλαμινης με δρασεις β2 αδρενεργικου αγωνιστη και μ3 μουσκαρινικου ανταγωνιστη
EA201390977A1 (ru) Комбинация агониста опиоидных рецепторов и антагониста опиоидных рецепторов для лечения болезни паркинсона
ECSP14003642A (es) 4-fenil-piridinas sustituidas para el tratamiento de enfermedades relacionadas con el receptor de nk1
DK2345653T3 (da) Morphinanforbindelser
MX342161B (es) Compuestos antagonistas selectivos de receptor nk-3 novedosos, composicion farmaceutica y metodos para utilizarse en trastornos transmitidos por receptores nk-3.
ME01532B (me) Jedinjenja
CY1119800T1 (el) Συνδυασμοι υποδοχεα της 5-ητ4 και αναστολεων ακετυλοχολινεστερασης για τη θεραπεια γνωστικων διαταραχων
CY1119047T1 (el) Υποκατεστημενα βενζαμιδια με δραστικοτητα εναντι υποδοχεων ερ4
EA201071169A1 (ru) ГИДРОКСИМЕТИЛПИРРОЛИДИНЫ В КАЧЕСТВЕ АГОНИСТОВ АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ β3
CY1120661T1 (el) Ανταγωνιστες υποδοχεα 5-ητ3 σεροτονινης για χρηση στη θεραπεια των αλλοιωτικων αιθουσαιων διαταραχων
UA107827C2 (en) Antibody cd40
MX2012010404A (es) Inhibidores heterociclicos de los receptores de histamina para el tratamiento de enfermedades.
EA201490161A1 (ru) Соединения - ингибиторы сигналинга, опосредуемого рецептором notch
MX2013005246A (es) Antagonistas del receptor del peptido relacionado con el gen de calcitonina (cgrp) de piperidinona carboxamida azaindano.
EA201400623A1 (ru) Новые 2h-индазолы в качестве антагонистов рецептора ep
CY1116720T1 (el) Παραγωγα 2-αμινο-3-(ιμιδαζολ-2-υλ)-πυριδιν-4-ονης και η χρηση τους ως αναστολεις κινασης υποδοχεα vegf
MX2015013328A (es) Uso de antagonistas del receptor de ep4 en el tratamiento de enfermedad de cartilago.
MA32945B1 (fr) Tétrahydropyrane spiro pyrrolidinone et pipéridinone substituées, leur préparation et leur utilisation thérapeutique
ATE557019T1 (de) Pyrrolidin-3-ylmethyl-amin als orexin- antagonisten